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Abstract
Background: Children with severe asthma have poor symptom control and elevated markers of airway oxidative and
nitrosative stress. Paradoxically, they have decreased airway levels of S-nitrosothiols (SNOs), a class of endogenous airway
smooth muscle relaxants. This deficiency results from increased activity of an enzyme that both reduces SNOs to ammonia
and oxidizes formaldehyde to formic acid, a volatile carboxylic acid that is more easily detected in exhaled breath
condensate (EBC) than SNOs. We therefore hypothesize that depletion of airway SNOs is related to asthma pathology, and
breath formate concentration may be a proxy measure of SNO catabolism.
Methods and Findings: We collected EBC samples from children and adolescents, including 38 with severe asthma, 46 with
mild-to-moderate asthma and 16 healthy adolescent controls, and the concentration of ionic constituents was quantified
using ion chromatography. The concentrations of EBC components with volatile conjugates were log-normally distributed.
Formate was the principal ion that displayed a significant difference between asthma status classifications. The mean EBC
formate concentration was 40% higher in samples collected from all asthmatics than from healthy controls (mean=5.7 mM,
mean6standard deviation=3.1210.3 mM vs. 4.0, 2.825.8 mM, p=0.05). EBC formate was higher in severe asthmatics than in
mild-to-moderate asthmatics (6.8, 3.7212.3 mM vs. 4.9, 2.828.7 mM, p=0.012). In addition, formate concentration was
negatively correlated with methacholine PC20 (r=20.39, p=0.002, asthmatics only), and positively correlated with the NO-
derived ion nitrite (r=0.46, p,0.0001) as well as with total serum IgE (r=0.28, p=0.016, asthmatics only). Furthermore,
formate was not significantly correlated with other volatile organic acids nor with inhaled corticosteroid dose.
Conclusions: We conclude that EBC formate concentration is significantly higher in the breath of children with asthma than
in those without asthma. In addition, amongst asthmatics, formate is elevated in the breath of those with severe asthma
compared to those with mild-to-moderate asthma. We suggest that this difference is related to asthma pathology and may
be a product of increased catabolism of endogenous S-nitrosothiols.
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Introduction
Individuals with severe asthma have poor symptom control
despite treatment with high doses of inhaled and systemic
corticosteroids [1]. In association with co-investigators involved in
the NIH/NHLBI Severe Asthma Research Program (SARP), we
have focused on the identification of clinical features and
biomarkers that differentiate severe from mild-to-moderate asthma
in childhood. Unlike their adult counterparts, children with severe
asthma are more atopic, have relatively mild airflow limitation at
baseline, and have a high degree of bronchodilator responsiveness
compared to children with mild-to-moderate asthma [2]. These
findings are associated with airway biochemical redox disturbances,
characterized by a shift in the balance of airway glutathione from
the reduced to the oxidized form, and increased concentrations of
the oxidant biomarkers H2O2, 8-isoprostane, and malondialdehyde
in airway surface liquid [3]. Furthermore, nitric oxide production is
altered in a way that supports the enrichment of toxic nitrogen
oxides [4]. Consequently, there is a relatively high level of oxidative
and nitrosative stress in the airways of children with severe asthma
as compared to those with mild-to-moderate asthma.
The difficulty of sampling airway biochemical markers in
humans presents a significant challenge to the evaluation of airway
status. Collection of bronchoalveolar lavage fluid and tracheal
aspirate has previously been used to determine the concentration
of S-nitrosothiols and other biomarkers in the airways [3,5,6,7].
Unfortunately, the invasive nature of these procedures makes them
less amenable in pediatric subjects and renders them unsuitable for
large clinical studies. On the other hand, the collection of exhaled
breath condensate (EBC) is a useful method to non-invasively
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non-volatile material entrained from collapsed menisci of lower
airway surface liquids [8,9,10] as well as volatile species that are
the product of gas-aqueous phase partitioning anywhere along an
exhaled breath flow path [11]. We have used ion chromatography
to quantify the concentration of inorganic and low molecular
weight organic ions in EBC [12], including both volatile and non-
volatile species. This technique yields highly reproducible results
with a detection limit in the tens to hundreds of nanomoles per
liter. The purpose of the current study was to quantify the volatile
and non-volatile ionic components of EBC of children enrolled in
SARP and to identify ionic constituents that best correlate with
clinical characteristics and established biomarkers. Furthermore,
we examined the possibility that individual ions or associations of
ions detected in EBC could be used to predict asthma severity.
Methods
Study sample and recruitment
This observational cross-sectional study was conducted based on
the characterization procedures developed by the NIH/NHLBI
Severe Asthma Research Program (SARP). The protocol was
approved by the Emory University Institutional Review Board,
and all procedures were monitored by an independent Data Safety
Monitoring Board. The legal guardians of enrollees provided
written informed consent, and the enrollees themselves gave assent
when appropriate. All SARP participants met criteria for asthma
as developed by the American Thoracic Society Guidelines.
To compare the ionic composition of EBC from asthmatic
children to that of non-asthmatic children, we analyzed EBC
samples collected from adolescent athletes enrolled in a previous
study. The features of this control group and study methods used
have been previously described [12,13]. Briefly, an EBC sample
was collected from each subject before and after outdoor exercise
on ten different days in late summer in Atlanta. The age range of
control subjects was 14–17 years while that of asthmatics was 6–17
years; however, the distribution of EBC formate concentration in
asthmatics 6–13 years was essentially the same as that of
asthmatics 14–17 years, suggesting that in this age range at least,
age does not have a significant influence on EBC formate
concentration. Since each participant in the control group
provided up to 20 repeated measures of EBC, we selected at
random one sample from each participant for our analyses.
Control group samples were collected both before and after
exercise, although the previous study did not find any influence of
exercise on EBC formate [12]. In addition, analysis of the control
group repeated measures indicated that the same-subject coeffi-
cient of variation for EBC formate was 33% over the course of the
two week sampling period.
Characterization procedures
SARP enrollees were designated as having either severe or mild-
to-moderate asthma based on the definition developed by the
American Thoracic Society Consensus Group (ATS Consensus on
Severe Asthma). This characterization procedure has been
previously described in detail [1] and has been validated by our
group for use with pediatric subjects [2]. Severe asthma is defined
by one or more major criteria (treatment with oral corticosteroids
for at least 50% of the year prior to enrollment and/or a high daily
dose of inhaled corticosteroids) and at least two minor criteria
(treatment with a second daily controller medication, daily use of a
short-acting bronchodilator, FEV1,80% predicted at baseline,
more than one emergency department visit for asthma in the
previous year, more than three oral corticosteroid bursts in the
previous year, deterioration following a reduction in corticosteroid
dose, or history of an asthma event requiring intubation).
Participants who did not meet this definition of severe asthma
were classified as having mild-to-moderate asthma.
Table 1. Characteristics of study participants
1.
severe (N=38) mild-to-moderate (N=46) non-asthmatic (N=16)
Age in years 11 (6–17) 10 (6–16) 15 (14–17)
Race: African American 28 (74) 20 (43) 5 (31)
Non-Hispanic white 7 (18) 20 (43) 11 (69)
other 3 (8) 6 (13)
Gender: male 19 (50) 30 (65) 9 (56)
female 19 (50) 15 (35) 7 (44)
BMI 20.4 (13.7238.0) 20.3 (13.2240.6) 19.8 (17.5223.5)
ICS dose (mg fluticasone equivalents/day)
2 853 (17621000) 352 (021000) 0 (0)
Serum IgE (IU/mL)
2 378 (425458) 142 (223484) not measured
Pulmonary function not measured
FVC (% predicted) 96 (652128) 103 (772141)
FEV1 (% predicted) 82 (482114) 97 (642123)
FEV1/FVC 0.74 (0.5920.96) 0.82 (0.5621.00)
FEF25–75 (% predicted) 67 (262193) 95 (322234)
DFEV1 post-bronchodilator 15% (21.4255%) 7.8% (25233%)
RV/TLC 0.34 (0.1620.86) 0.24 (0.1420.39) not measured
Methacholine PC20 1.11 (0.14220) 5.26 (0.09220) not measured
1Values are either frequency (percentage) or mean (range).
2Data were logarithmically transformed prior to analysis.
doi:10.1371/journal.pone.0011919.t001
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EBC was collected using the R-tubeH (Respiratory Research,
Charlottesville, VA). EBC pH was measured both before and after
deaeration with argon. A separate aliquot was analyzed by ion
chromatography using a previously described method [12]. Since
the concentrations of ionic species with volatile conjugates are log-
normally distributed, analyses of EBC constituents were performed
using log-transformed values. The mean and spread of log-
transformed variables were subsequently reverted to units of
micromolar concentration for readability purposes, but note that
the resulting ranges of mean6standard deviation are not
symmetric with respect to the mean on a linear scale. We used
SASH software (Version 9.2, SAS Institute Inc., Cary, NC) to
conduct principal component analysis of EBC constituents,
bivariate linear correlations between each EBC component with
all others and with individual clinical indicators related to asthma
severity, and Student’s t-tests to determine significant differences
between the asthma severity classes.
Results
Subject characterization
The study sample included 38 children with severe asthma, and
46 children with mild-to-moderate asthma as well as 16 healthy
adolescents enrolled in a previous study (Table 1). Compared to
children with mild-to-moderate asthma, children with severe
asthma were more likely to be self-identified as African-American,
were treated with higher doses of inhaled corticosteroids, and were
more likely to have been admitted to the hospital in the past.
Likewise children with severe asthma had relatively reduced lung
function, including lower baseline FEV1 percent predicted, lower
FEV1/FVC, and air trapping as indicated by a higher RV/TLC
ratio. Although children with severe asthma exhibited mild airflow
obstruction at baseline, FEV1 percent predicted increased
significantly following maximum bronchodilation, and post-
bronchodilator spirometric variables in children with severe
asthma were not significantly different from those of children
Figure 1. Principal Component Analysis of EBC collected from all subjects. Each cluster is scaled according to the fraction of
the total variance explained by that principal component. The Pearson correlation coefficients are given between all species within each
cluster.
doi:10.1371/journal.pone.0011919.g001
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more atopic, with higher serum IgE and a greater number of
positive skin prick tests to aeroallergens.
Principal component analysis and bivariate correlations
Nearly all EBC samples contained quantifiable concentrations
of the anions lactate, acetate, propionate, formate, butyrate,
pyruvate, chloride, nitrite, nitrate, sulfate, and oxalate as well as
the cations sodium, ammonium, potassium, magnesium, and
calcium. The concentration of ammonium was approximately an
order of magnitude greater than other measured ions.
Principal component analysis identified three clusters of EBC
constituents that account for most of the variance in ionic
composition (Figure 1). The first principal component, account-
ing for 32% of the total variance, was closely correlated
(p,0.0001) with the non-volatile species lactate (r=0.92), chloride
(r=0.81), sulfate (r=0.36), sodium (r=0.82) and potassium
(r=0.95). The second component, accounting for 22% of the
variance, was correlated (p,0.0001) with species with a volatile
conjugate such as acetate (r=0.79), propionate (r=0.90), and
butyrate (r=0.78) and was inversely correlated with ammonium
(r=20.59). The third principal component, accounting for 14%
of the variance, was correlated (p,0.0001) with formate (r=0.62)
and nitrite (r=0.84). These three clusters likely represent groups of
ions with similar sources: non-volatile ions associated with fluid
secretion (chloride, sodium, potassium), volatile organics associat-
ed with metabolic processes (acetate, propionate, ammonium) and
volatile species with a source distinct from other volatiles, perhaps
related to nitrosylative processes (formate, nitrite).
Examination of the bivariate correlations between ions revealed
a similar pattern: many non-volatile species were correlated with
one other as were several organic species with a volatile conjugate,
namely acetate, propionate, and butyrate. Ammonium was
inversely correlated with these acidic species but did not otherwise
exhibit a relationship with any other constituent. In addition,
formate was significantly correlated with two clinical variables (not
measured in controls), namely the methacholine PC20 (for log-
transformed formate, r=20.39, p=0.002) and serum IgE
(r=0.28, p=0.016).
Differences between asthma severity classifications
The key differences in EBC ionic composition between asthma
severity classifications were found to be formate and to a lesser
extent, nitrite concentration. The mean EBC formate concentra-
tion was 40% higher in samples collected from all asthmatics than
from healthy controls (mean=5.7 mM, mean6standard devia-
tion=3.1210.3 mM vs. 4.0, 2.825.8 mM, p=0.05). In addition,
EBC formate was significantly higher in severe asthmatics than in
mild-to-moderate asthmatics (Figure 2). EBC nitrite likewise
displayed a statistically-significant difference between asthmatic
subjects and healthy controls (0.92, 0.3722.3 mM vs. 0.24,
0.1320.44 mM, p,0.0001), though the difference between severe
and mild-to-moderate asthmatics was modest and not significant
(1.0, 0.4322.3 mM vs. 0.86, 0.3322.3 mM, p=0.45). Other EBC
ions either did not display a difference between groups and/or the
difference was not significant.
Discussion
Of the ionic components measured in EBC collected from
asthmatic and healthy children and adolescents, formate displayed
the most notable difference between asthma severity classifications.
Principal component analysis suggests that the source of formate in
EBC is distinct from most other measured ionic species. Despite its
high volatility in the non-ionized state, formate is not highly
correlated with other volatile organic acids commonly detected in
EBC. In addition, EBC formate is associated with the NO-derived
ion nitrite, which itself displays more modest stratification by
asthma severity. Furthermore, EBC formate was significantly
correlated with clinical variables associated with asthma severity,
namely methacholine PC20 and serum IgE. Given the strength of
the significant difference in EBC formate between asthma severity
classifications, we suggest that the higher formate seen in the
breath condensate of severe asthmatics may be related to asthma
pathology.
A potential mechanism that conceptually explains both elevated
breath formate levels and their association with asthma severity
involves the catabolism of S-nitrosothiols (SNOs). SNOs are a
novel class of endogenous bronchodilators [6] that are formed by
the addition of nitrosonium to peptide or protein sulfhydryl group
s[14,15,16,17]. These compounds serve as a stable reservoir of
nitrosonium [18,19] and play a vital role both in airway smooth
muscle relaxation and in prevention of tachyphylaxis of the b2
adrenoreceptor. The principal SNO in healthy human airways is
S-nitrosoglutathione (GSNO) [6]. GSNO activity is regulated by
an alcohol dehydrogenase enzyme [20,21,22,23] referred to in this
context as GSNO-reductase (GSNOR). In the presence of NADH,
GSNOR reduces GSNO to form glutathione sulfinamide [22];
however, GSNOR also oxidizes the formaldehyde-glutathione
Figure 2. The distributions of EBC formate concentration for
healthy adolescents and children with mild-to-moderate or
severe asthma. Markers represent individual measurements; boxes
represent the 25
th,5 0
th, and 75
th percentiles; whiskers represent the
mean6standard deviation.
doi:10.1371/journal.pone.0011919.g002
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[22,24]. S-formylglutathione is in turn hydrolyzed to glutathione
and formate [25]. Thus an increase in GSNOR activity would be
expected to lead to both a loss of GSNO [24,26] and an increase
in formate production.
A growing body of evidence suggests that GSNO dysregulation
is intimately involved in the pathology of asthma. Analysis of fluids
obtained from the airways of children with respiratory failure and
severe asthma have been found to have lower levels of SNOs
relative to healthy children [7]. This depletion is likely related to
increased GSNOR activity. Que et al. [27] have shown that mice
deficient in GSNOR have high levels of airway GSNO and are
protected from ovalbumin-induced airway hyperresponsiveness to
methacholine whereas hyperresponsive mice have high levels of
GSNOR in their airways. This same group subsequently
demonstrated that GSNOR activity is higher in asthmatic humans
than in controls and is inversely correlated with both airway S-
nitrosothiol content and methacholine PC20 [28]. Whalen et al.
[29] found that GSNOR prevents S-nitrosylation of G-protein-
coupled receptor kinase 2 and that GSNOR deficient mice are
protected from tachyphylaxis to b2 agonists. We therefore
hypothesize that SNO degradation perturbs airway tone in asthma
and suggest that GSNO may play an important role in future
therapeutic strategies for the treatment of asthma.
Unfortunately, the concentrations of SNOs and GSNOR in
human airways have proven difficult to evaluate. The S-nitrosothiol
bond is notoriously labile, introducing the potential for false positives
and negatives [30], and in addition, SNO concentrations in the
airways of asthmatics are extremely low, indeed, nearly undetectable
in samples of airway fluid. This problem is compounded by high
levels of protons and nitrite in asthmatic airways [6,31], each of
which can artifactually increase measured SNO levels. Formic acid
on the other hand is a volatile species related to S-nitrosothiol
catabolismandiseasilydetectableas formateinEBCwithnosample
preparation needed [12]. For non-volatile compounds, the variable
degreeofdilution withwater vaporcanpresent achallenge toproper
interpretation of EBC concentration data [32,33]; however, for
volatile compounds such as formic acid, EBC concentration is
influenced by factors related to volatilization more so than water
vapor condensation. For example, the fraction of formic acid in
epithelial lining fluid that is volatile is pH-dependent (0.55% is
volatile at pH=6.0, 0.17% at pH=6.5, and 0.055% at pH=7.0),
and in addition, volatilization from non-airway sources could
contribute to EBC formate concentration. Furthermore, the
concentration of the S-hydroxymethylglutathione substrate is related
to formaldehyde exposure [24]; hence formaldehyde exposure
would be expected to increase EBC formate. If analysis of EBC
formate concentration is indeed a valid proxy for GSNOR activity,
EBC formate might be used as a non-invasive measure to identify
asthmatic patients at risk for GSNO depletion to receive therapies
designed to enhance or replace endogenous GSNO levels.
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